Journal
CELL REPORTS
Volume 11, Issue 4, Pages 630-644Publisher
CELL PRESS
DOI: 10.1016/j.celrep.2015.03.050
Keywords
-
Categories
Funding
- Howard Temin Pathway to Independence Award K99/R00 from NIH/NCI [R00CA140789]
- Interdisciplinary Training in Genome Sciences grant from NIH/NHGRI [T32 HG00035]
- National Science Foundation grant [DBI-1355899]
- South Sound CARE Foundation
- Washington Research Foundation
- Gary E. Milgard Family Foundation
Ask authors/readers for more resources
Triple-negative breast cancer is a heterogeneous disease characterized by poor clinical outcomes and a shortage of targeted treatment options. To discover molecular features of triple-negative breast cancer, we performed quantitative proteomics analysis of twenty human-derived breast cell lines and four primary breast tumors to a depth of more than 12,000 distinct proteins. We used this data to identify breast cancer subtypes at the protein level and demonstrate the precise quantification of biomarkers, signaling proteins, and biological pathways by mass spectrometry. We integrated proteomics data with exome sequence resources to identify genomic aberrations that affect protein expression. We performed a high-throughput drug screen to identify protein markers of drug sensitivity and understand the mechanisms of drug resistance. The genome and proteome provide complementary information that, when combined, yield a powerful engine for therapeutic discovery. This resource is available to the cancer research community to catalyze further analysis and investigation.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available